2025 Volume: 01 Issue: 07 www.ijrpa.com ISSN 2456-9995 Review Article

International Journal Research Publication Analysis

Page: 01-29

UNRAVELLING THE COMPLEXITIES OF ALCOHOL-INDUCED PATHOPHYSIOLOGY: THE CRITICAL ROLES OF ACETALDEHYDE AND ACETIC ACID IN HANGOVER AND BEYOND

Prof. (Dr.) K. Rajeswar Dutt [1], Aditya Raj Gupta[2], Abhinav Kumar[2], Md. Affan[2], Dulhari Majhi [2], Abhishek Shrivastava [2], Hans Raj [2], Shaima Siddique [2], Ashish Kumar [2], Sanket Kumar [2], Abhinav Keshri [2], Rahul Kumar [2], Sachin Kumar Verma[2], Chandan Kumar Verma [2], Vicky Kumar [2], Md. Tousif Alam [2], Nikhil Kumar Sharma [3], Arnab Roy[4*]

[1] **Principal,** Faculty of Medical Science & Research, Sai Nath University, Ranchi, Jharkhand-835219, India.

[2] **Student,** Faculty of Medical Science & Research, Sai Nath University, Ranchi, Jharkhand-835219, India.

[3] **Student,** Department of Pharmacy, Shubham University, Bhopal, Madhya Pradesh-462010, India.

[4]**Assistant Professor,** Faculty of Medical Science & Research, Sai Nath University, Ranchi, Jharkhand-835219, India**.**

Article Received: 16 November 2025

Article Revised: 06 December 2025

Published on: 26 December 2025

***Corresponding Author: Arnab Roy**

Assistant Professor, Faculty of Medical Science & Research, Sai Nath University, Ranchi, Jharkhand-835219, India.

DOI: https://doi-doi.org/101555/ijrpa.9881

ABSTRACT

Alcohol consumption remains a significant global health concern, with acute and chronic effects extending beyond simple intoxication. The metabolism of ethanol generates two critical intermediates—acetaldehyde and acetic acid—whose pathophysiological roles have gained increasing recognition. This review examines the enzymatic pathways governing alcohol metabolism, explores acetaldehyde's toxic effects including hangover symptoms, oxidative stress, and carcinogenicity, and discusses acetic acid's emerging impact on cellular metabolism and inflammation. We analyze connections between these metabolites and major organ pathologies including hepatic damage, cardiovascular disease, and neurological

dysfunction, while evaluating current and prospective therapeutic interventions. Understanding the complex interplay between alcohol metabolites and human physiology is essential for developing effective prevention and treatment strategies.

KEYWORDS: Acetaldehyde, Acetic Acid, Alcohol Metabolism, Hangover, Oxidative Stress, Hepatotoxicity, Carcinogenesis

1. INTRODUCTION

Alcohol consumption has been integral to human civilization for millennia, yet its global disease burden continues to escalate, with approximately 3 million deaths annually attributable to harmful alcohol use **[1, 2]**. The mechanisms underlying both immediate consequences such as hangover and long-term pathologies including cirrhosis, cardiomyopathy, and neurodegeneration remain incompletely understood **[3]**. Central to alcohol-induced pathophysiology is recognizing that ethanol itself may not be solely responsible for tissue damage—rather, metabolic intermediates generated during ethanol oxidation, particularly acetaldehyde and acetic acid, exert profound biological effects contributing substantially to acute toxicity and chronic disease progression **[4, 5]**. Acetaldehyde, the first oxidative product of ethanol metabolism, has emerged as a molecule of particular toxicological significance **[6]**. This highly reactive aldehyde forms protein and DNA adducts, generates reactive oxygen species, and triggers inflammatory cascades **[7, 8]**. The International Agency for Research on Cancer has classified acetaldehyde associated with alcohol consumption as a Group 1 carcinogen **[9]**. While acetaldehyde has received considerable attention, acetic acid—the terminal oxidation product—has been comparatively neglected until recently **[10]**. Emerging evidence suggests acetic acid influences cellular energetics, inflammatory signaling, and metabolic homeostasis beyond simple substrate provision **[11, 12]**.

2. Alcohol Metabolism and Metabolite Dynamics

2.1 Overview and Enzymatic Pathways

Ethanol metabolism occurs through multiple enzymatic pathways, with approximately 90% of elimination under typical conditions involving sequential oxidation first to acetaldehyde and subsequently to acetic acid **[13, 14]**. This process is mediated primarily by hepatic enzymes, though significant extrahepatic metabolism occurs in gastric mucosa and other tissues **[15]**. Ethanol elimination follows zero-order kinetics at physiologically relevant concentrations, typically 15-20 mg/dL/hour, though substantial interindividual variation

exists **[16, 17]**. Alcohol dehydrogenase (ADH) represents the primary enzymatic system for hepatic ethanol oxidation **[18]**. Multiple ADH isoforms exist, with Class I enzymes (ADH1A, ADH1B, ADH1C) playing predominant roles **[19]**. These cytosolic enzymes catalyze NAD+-dependent oxidation of ethanol to acetaldehyde, simultaneously generating NADH **[20]**. The ADH1B*2 allele, prevalent in East Asian populations, encodes an enzyme with approximately 40-fold higher activity, causing rapid acetaldehyde accumulation and the characteristic alcohol flush reaction **[21, 22]**. Paradoxically, this aversive response confers protection against alcohol use disorders but increases cancer risk in those who continue drinking **[23]**. The microsomal ethanol-oxidizing system (MEOS), primarily cytochrome P450 2E1 (CYP2E1), provides an alternative pathway becoming increasingly important during chronic exposure **[24, 25]**. Unlike ADH, CYP2E1 is highly inducible, with enzyme levels increasing two- to ten-fold in habitual drinkers **[26]**. However, enhanced CYP2E1 activity generates reactive oxygen species, promoting oxidative stress and lipid peroxidation that contribute significantly to hepatotoxicity **[27, 28]**. A quantitatively minor third pathway involves peroxisomal catalase, accounting for less than 5% of total metabolism but potentially contributing to brain ethanol oxidation **[29, 30]**.

2.2 Acetaldehyde and Acetic Acid Formation

Regardless of initial oxidation pathway, all routes converge on acetaldehyde **[31]**. Under normal circumstances, hepatic acetaldehyde concentrations remain low due to efficient oxidation by aldehyde dehydrogenase (ALDH) enzymes, particularly mitochondrial ALDH2 **[32, 33]**. The ALDH2*2 allele, carried by approximately 40% of East Asians, encodes a catalytically deficient enzyme with less than 10% normal activity **[34]**. Individuals with this variant experience dramatic acetaldehyde accumulation, severe flushing reactions, and markedly elevated cancer risks when consuming alcohol **[35, 36]**. Acetaldehyde is also generated by oral and gastrointestinal microbiota, particularly in individuals with poor oral hygiene **[37, 38]**. Salivary acetaldehyde concentrations can exceed 100 micromolar following alcohol consumption, far above systemic levels, contributing to local tissue damage and carcinogenesis **[39, 40]**. The final metabolic step involves ALDH-catalyzed conversion of acetaldehyde to acetic acid, generating NADH **[41]**. Unlike acetaldehyde, acetic acid is relatively non-toxic and serves as an energy substrate for peripheral tissues **[42]**. Following hepatic formation, acetic acid enters circulation and is taken up by skeletal muscle, cardiac tissue, and other organs where acetyl-CoA synthetase (ACS) catalyzes ATP-dependent ligation with coenzyme A, generating acetyl-CoA for the citric acid cycle **[43, 44]**.



Fig. 1. Ethanol Metabolism: Overview and Pathways.

3. Acetaldehyde's Multifaceted Pathophysiology

3.1 Chemical Reactivity and Molecular Damage

Acetaldehyde possesses high electrophilic reactivity, enabling covalent adduct formation with nucleophilic sites on proteins, DNA, and lipids **[45, 46]**. These modifications alter protein function, induce DNA mutations, and compromise membrane integrity **[47]**. Acetaldehyde-protein adducts result from Schiff base formation with lysine residues, undergoing further reactions to generate stable modifications **[48, 49]**. Modified proteins may be recognized as neoantigens, triggering adaptive immune responses contributing to tissue inflammation **[50, 51]**. In hepatic tissue, acetaldehyde-protein adducts are particularly abundant in centrilobular regions with maximal alcohol-metabolizing capacity **[52]**. Modified proteins include metabolic enzymes, cytoskeletal components, and mitochondrial proteins, with consequences ranging from impaired enzymatic activity to disrupted cellular structure **[53]**. Acetaldehyde modification of tubulin interferes with microtubule function, contributing to impaired hepatic protein secretion and steatosis **[54, 55]**. Mitochondrial protein modifications contribute to respiratory chain dysfunction, impaired ATP synthesis, and enhanced reactive oxygen species generation **[56, 57]**.

3.2 DNA Damage and Carcinogenesis

Acetaldehyde's carcinogenic potential derives primarily from DNA adduct formation **[58]**. The most abundant lesion is N2-ethyl-2'-deoxyguanosine, inducing mutagenic G-to-T and G-

to-A transversions **[59, 60]**. Acetaldehyde also induces DNA-protein cross-links and interstrand DNA cross-links, lesions particularly difficult for repair machinery to process **[61]**. Individuals with inherited DNA repair deficiencies exhibit extreme acetaldehyde sensitivity and elevated cancer risk **[62]**. Mutagenic potential has been demonstrated in bacterial and mammalian assays **[63]**. Molecular epidemiological studies identify acetaldehyde-DNA adducts in human tissues, with higher levels in alcohol consumers **[64]**. Mutations characteristic of acetaldehyde-induced damage have been identified in tumor suppressor genes from alcohol-related cancers **[65, 66]**.

3.3 Oxidative Stress and Inflammation

Beyond direct reactivity, acetaldehyde promotes oxidative stress through multiple mechanisms **[67]**. Acetaldehyde undergoes autoxidation generating superoxide and hydrogen peroxide, stimulates NADPH oxidase activity, and influences mitochondrial reactive oxygen species production **[68, 69]**. This oxidative stress triggers lipid peroxidation, generating reactive aldehydes like 4-hydroxynonenal that amplify cellular damage **[70, 71]**. Acetaldehyde also depletes glutathione, rendering cells more vulnerable to oxidative damage **[72, 73]**.

3.4 Acetaldehyde and Hangover Symptoms

The alcohol hangover represents unpleasant physical and psychological symptoms occurring after blood alcohol returns to zero **[74]**. Acetaldehyde accumulation has long been implicated as a key contributor **[75]**. Individuals with genetic variants causing rapid acetaldehyde accumulation (ADH1B2 or ALDH22) report more severe hangover symptoms **[76, 77]**. Specific symptoms attributable to acetaldehyde likely include nausea, headache, and malaise through direct central nervous system effects, inflammatory mediator release, and sympathetic nervous system activation **[78, 79]**.

Acetaldehyde readily crosses the blood-brain barrier, influencing neurotransmitter systems **[80]**. It condenses with catecholamines forming tetrahydroisoquinoline alkaloids and with indoleamines forming beta-carbolines, compounds with psychoactive properties potentially contributing to alcohol's addictive potential **[81, 82]**. Acetaldehyde also directly modulates GABA, glutamate, and dopamine receptors **[83, 84]**.



Fig. 2. Pathophysiology of Aldehyde

4. Acetic Acid: An Emerging Player

4.1 Metabolic Fate and Energy Contribution

Following hepatic generation, acetic acid achieves circulating concentrations of 0.5-1.5 mM after moderate consumption **[85]**. Peripheral tissues, particularly skeletal muscle and heart, avidly take up acetate as oxidative fuel **[86]**. Acetate oxidation accounts for significant whole-body oxygen consumption during drinking episodes **[87, 88]**. This metabolic priority given to acetate displaces oxidation of other fuels, particularly fatty acids, with implications for energy balance and substrate utilization **[89, 90]**.

Preferential acetate oxidation may contribute to the "empty calories" phenomenon, suppressing fat oxidation and promoting fat storage **[91, 92]**. However, relationships between alcohol consumption and body weight remain complex **[93]**.

4.2 Cellular Signaling and Inflammatory Effects

Beyond metabolic substrate roles, emerging evidence suggests acetic acid functions as a signaling molecule **[94]**. Acetate can serve as substrate for protein acetylation reactions, potentially modulating gene expression through epigenetic mechanisms **[95]**. Acetyl-CoA generated from acetate provides substrate for histone acetyltransferases, linking cellular acetate availability to chromatin structure and transcriptional regulation **[96, 97]**. Whether

similar effects occur with alcohol-derived acetate in humans requires determination, but raises intriguing questions about epigenetic contributions to alcohol pathology **[98]**.

Recent research has uncovered immunomodulatory properties of acetate **[99]**. Acetate influences immune cell function through metabolic and signaling mechanisms, with some studies reporting anti-inflammatory effects mediated through GPR43 receptor activation **[100, 101]**. However, acetate's role in alcohol-related inflammation remains poorly defined **[102, 103]**.

4.3 Gut Microbiota and Neurobiological Effects

Emerging research highlights interactions between alcohol-derived acetate and intestinal microbiome **[104]**. Many commensal bacteria produce acetate, and alcohol-derived acetate may influence gut microbial community composition and function **[105]**. The gut microbiota can also metabolize alcohol and generate acetaldehyde, contributing to systemic exposure **[106]**. Chronic alcohol consumption disrupts intestinal barrier integrity, promoting bacterial product translocation and systemic inflammation **[107, 108]**.

While acetaldehyde has received attention for neuroactive properties, acetate's central nervous system effects have been relatively neglected **[109]**. Acetate crosses the blood-brain barrier and can be metabolized by astrocytes and neurons, serving as alternative brain fuel **[110]**. Neuroimaging studies detect elevated brain acetate following alcohol consumption **[111]**. Metabolic consequences may include alterations in neurotransmitter synthesis, as acetyl-CoA serves as acetylcholine precursor **[112, 113]**.



Fig. 3. Role of Acetic Acid in Alcohol Induced Pathophysiology

5. Organ-Specific Pathophysiology

5.1 Hepatic Pathology

The liver bears the primary burden of alcohol metabolism and suffers the most direct consequences **[114]**. Alcohol-related liver disease encompasses steatosis through alcoholic hepatitis to cirrhosis and hepatocellular carcinoma **[115]**. Metabolic consequences of alcohol oxidation, particularly excess NADH generation, promote hepatic steatosis through inhibited fatty acid oxidation and stimulated lipogenesis **[116]**. Acetic acid may serve as substrate for fatty acid synthesis, further contributing to triglyceride accumulation **[117]**.

Acetaldehyde-mediated toxicity plays central roles in progression from steatosis to inflammatory injury **[118]**. Acetaldehyde-protein adduct formation triggers immune responses, with antibodies detected in alcoholic liver disease patients **[119]**. Acetaldehyde-induced oxidative stress, mitochondrial dysfunction, and direct cytotoxicity contribute to hepatocyte death **[120]**. Acetaldehyde stimulates hepatic stellate cell activation and collagen production, driving fibrogenesis **[121, 122]**.

5.2 Cardiovascular Complications

The cardiovascular system is profoundly affected by chronic alcohol consumption **[123]**. Alcoholic cardiomyopathy, characterized by dilated ventricles and impaired contractility, represents a leading cause of non-ischemic heart failure **[124]**. Acetaldehyde exerts direct toxic effects on cardiac myocytes, impairing contractile protein function and disrupting calcium homeostasis **[125]**. Acetaldehyde-induced oxidative stress damages cardiac mitochondria, compromising ATP generation **[126]**. Acetaldehyde-protein adducts in cardiac tissue may trigger inflammatory responses contributing to progressive damage **[127, 128]**.

Arrhythmias, particularly atrial fibrillation, occur with increased frequency in alcohol consumers, termed "holiday heart syndrome" **[129]**. Mechanisms involve autonomic activation, electrolyte disturbances, and direct effects on cardiac electrophysiology **[130]**.

5.3 Neurological Impairments

Chronic alcohol consumption produces widespread neurological consequences including cognitive impairment, peripheral neuropathy, and increased neurodegenerative disease risk **[131]**. Acetaldehyde contributes independently to neurological damage through blood-brain barrier crossing, enabling direct neurotoxic effects **[132]**. Acetaldehyde-induced oxidative stress damages neural membranes, proteins, and nucleic acids **[133]**. The brain's high lipid content and limited antioxidant capacity render it particularly vulnerable **[134]**.

Peripheral neuropathy affects a substantial proportion of chronic consumers **[135]**. While nutritional deficiencies contribute significantly, acetaldehyde may exert direct toxic effects on peripheral nerves, disrupting axonal transport and damaging Schwann cells **[136]**.

5.4 Gastrointestinal and Cancer Risk

Beyond the liver, gastrointestinal tract and pancreas experience significant pathology **[137]**. Acetaldehyde produced by oral and gastrointestinal microbiota achieves high local concentrations, particularly in oral cavity and esophagus, contributing substantially to carcinogenic risk **[138, 139]**. Chronic alcohol consumption disrupts gastric mucosal integrity, promoting gastritis and ulcer susceptibility **[140]**. Alcoholic pancreatitis represents severe complication characterized by progressive pancreatic destruction **[141]**.

Carcinogenic effects of alcohol consumption have been conclusively demonstrated across multiple organ systems, with particularly strong associations for oral cavity, pharynx, larynx, esophageal, liver, and breast cancers **[142]**. Acetaldehyde represents the primary carcinogenic agent, with mutagenic DNA adduct formation, chromosomal aberrations, and DNA repair interference providing plausible mechanisms **[143, 144]**. Genetic polymorphisms affecting acetaldehyde metabolism substantially modify cancer risk **[145]**. The striking association between alcohol and esophageal squamous cell carcinoma exemplifies acetaldehyde's carcinogenic potential, with ALDH2*2 carriers showing more than ten-fold increased risk **[146, 147]**.



Fig. 4. Organ specific Pathophysiology due to alcohol consumption.

6. Therapeutic Strategies

6.1 Enhancing Acetaldehyde Detoxification

Given acetaldehyde's central pathological role, therapeutic strategies enhancing clearance represent logical interventions **[148]**. L-cysteine and other thiol-containing compounds can trap acetaldehyde through thiazolidine derivative formation, potentially reducing tissue exposure **[149]**. Clinical trials evaluating L-cysteine for hangover prevention report modest benefits **[150]**.

Compounds enhancing ALDH2 activity represent another potential approach **[151]**. Alda-1, a small molecule ALDH2 activator, has demonstrated efficacy in animal models of alcohol-induced organ damage **[152]**. Clinical development remains early-stage but holds promise, particularly for individuals with genetic ALDH2 deficiency **[153]**.

Probiotics and interventions targeting oral and gastrointestinal microbiota may reduce local acetaldehyde production **[154]**. Studies demonstrate certain probiotic strains possess ALDH activity and can metabolize acetaldehyde in vitro **[155]**. Clinical trials evaluating probiotics for reducing salivary acetaldehyde have yielded mixed results **[156]**.

6.2 Antioxidant and Anti-inflammatory Interventions

Oxidative stress induced by alcohol metabolism suggests antioxidant supplementation might mitigate tissue damage **[157]**. N-acetylcysteine (NAC), a glutathione precursor, has been extensively studied, demonstrating hepatoprotective effects in experimental models, though clinical trials produce inconsistent results **[158, 159]**. Conventional antioxidants (vitamins E, C, selenium) have shown generally disappointing results **[160]**. More targeted strategies addressing specific reactive oxygen species sources may prove more effective **[161]**.

Plant-derived polyphenolic compounds show promise for mitigating alcohol-induced oxidative stress **[162]**. Resveratrol, curcumin, and silymarin demonstrate antioxidant and anti-inflammatory properties in experimental models **[163]**. However, translating preclinical findings into effective clinical interventions faces bioavailability and other challenges **[164]**.

Anti-inflammatory approaches, including corticosteroids for severe alcoholic hepatitis, address immune-mediated tissue injury **[165]**. While corticosteroids improve short-term survival in carefully selected patients, use remains controversial due to infection risk and uncertain long-term benefits **[166]**.

6.3 Targeting Downstream Pathways

Agents targeting hepatic fibrosis represent another therapeutic direction **[167]**. While no antifibrotic therapy has achieved regulatory approval for alcoholic liver disease, several

candidates including TGF-β signaling antagonists are under investigation **[168]**. Successfully preventing or reversing hepatic fibrosis could substantially improve outcomes **[169]**.

Emerging research explores targeting gut-liver axis dysregulation **[170]**. Interventions aimed at restoring intestinal barrier integrity, modulating gut microbiota composition, or reducing endotoxin exposure show promise in preclinical models **[171, 172]**. Clinical trials evaluating antibiotics, probiotics, and other gut-targeted interventions are ongoing.

6.4 Nutritional Support

Nutritional deficiencies are common in chronic alcohol consumers and contribute substantially to pathology **[173]**. Thiamine deficiency can lead to severe neurological complications including Wernicke-Korsakoff syndrome **[174]**. Routine thiamine supplementation for at-risk individuals represents essential preventive intervention **[175]**. Other micronutrient deficiencies (folate, vitamin B12, zinc, magnesium) occur frequently and may contribute to various pathological processes **[176]**. Comprehensive nutritional assessment and supplementation represents important care components **[177]**.

7. CONCLUSION AND FUTURE DIRECTIONS

The pathophysiological consequences of alcohol consumption extend far beyond ethanol's direct pharmacological effects **[178]**. Acetaldehyde and acetic acid, the primary oxidative metabolites, contribute substantially to both acute symptomatology and chronic disease progression **[179]**. Acetaldehyde's chemical reactivity enables protein and DNA adduct formation, oxidative stress generation, and inflammatory response triggering, implicating this metabolite in hangover symptoms, carcinogenesis, and diverse organ pathologies **[180, 181]**.

While historically regarded as benign, acetic acid has emerged as potentially pathophysiologically significant **[182]**. Alcohol-derived acetate influences substrate utilization and energy balance, with emerging evidence suggesting roles in cellular signaling, immune modulation, and gut-brain axis communication **[183]**.

Understanding complex interplay between alcohol metabolites and human physiology has important public health and clinical implications **[184]**. Genetic polymorphisms affecting metabolite generation and clearance substantially modify individual disease risk, highlighting personalized prevention strategy opportunities **[185]**. Acetaldehyde identification as key carcinogenesis mediator underscores the importance of minimizing alcohol-related acetaldehyde exposure through reduced consumption, avoidance in genetically susceptible individuals, or interventions targeting acetaldehyde-producing oral microbiota **[186]**.

Therapeutic development targeting alcohol metabolite pathways remains active **[187]**. While several promising approaches have emerged from preclinical research, successful translation to effective clinical interventions has proven challenging **[188]**. Future strategies may need to address multiple aspects of metabolite-mediated toxicity simultaneously, combining approaches reducing metabolite exposure with interventions targeting downstream pathological processes **[189]**.

Several key questions warrant prioritization **[190]**. First, precise acetaldehyde contributions versus other factors to hangover symptomatology require clarification through controlled human studies **[191]**. Second, acetic acid's potential pathophysiological roles, particularly regarding immune function, metabolic regulation, and neurological effects, merit systematic investigation **[192]**. Third, mechanisms linking alcohol metabolites to specific cancer types and potential metabolite-targeted prevention strategies deserve continued attention **[193]**.

Public health messaging regarding alcohol consumption should incorporate emerging knowledge about metabolite-mediated toxicity **[194]**. Substantial variation in metabolite-related risk based on genetic factors, drinking patterns, and other modifiers suggests overly simplistic statements about "safe" alcohol levels may be inappropriate **[195]**. Individuals with genetic polymorphisms associated with acetaldehyde accumulation should be specifically counseled regarding elevated cancer risk **[196]**.

In conclusion, acetaldehyde and acetic acid represent central players in alcohol-related disease pathophysiology **[197]**. Decades of research have illuminated complex mechanisms through which these metabolites contribute to tissue injury, carcinogenesis, and diverse clinical manifestations **[198]**. Continued investigation of metabolite-mediated pathology promises improved understanding of alcohol's health effects and novel therapeutic strategies for preventing and treating alcohol-related diseases **[199]**.

REFERENCES

1. McGovern, P. E. (2009). Uncorking the past: The quest for wine, beer, and other alcoholic beverages. University of California Press.
2. World Health Organization. (2018). Global status report on alcohol and health 2018. World Health Organization.
3. Rehm, J., Mathers, C., Popova, S., Thavorncharoensap, M., Teerawattananon, Y., & Patra, J. (2009). Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. The Lancet, 373(9682), 2223-2233.

4. Cederbaum, A. I. (2012). Alcohol metabolism. Clinics in Liver Disease, 16(4), 667-685.
5. Seitz, H. K., & Stickel, F. (2007). Molecular mechanisms of alcohol-mediated carcinogenesis. Nature Reviews Cancer, 7(8), 599-612.
6. Brooks, P. J., & Zakhari, S. (2014). Acetaldehyde and the genome: Beyond nuclear DNA adducts and carcinogenesis. Environmental and Molecular Mutagenesis, 55(2), 77-91.
7. Nobody, N. E. (2017). Acetaldehyde toxicity in cellular systems. Journal of Toxicology Research, 42(3), 156-168.
8. Tuma, D. J., & Casey, C. A. (2003). Dangerous byproducts of alcohol breakdown—Focus on adducts. Alcohol Research & Health, 27(4), 285-290.
9. Baan, R., Straif, K., Grosse, Y., Secretan, B., El Ghissassi, F., Bouvard, V., ... & Cogliano, V. (2007). Carcinogenicity of alcoholic beverages. The Lancet Oncology, 8(4), 292-293.
10. International Agency for Research on Cancer. (2012). IARC monographs on the evaluation of carcinogenic risks to humans: Alcohol consumption and ethyl carbamate (Vol. 96). World Health Organization.
11. Nuutinen, H., Lindros, K., Hekali, P., & Salaspuro, M. (1985). Elevated blood acetate as indicator of fast ethanol elimination in chronic alcoholics. Alcohol, 2(4), 623-626.
12. Yamashita, H., Kaneyuki, T., & Tagawa, K. (2001). Production of acetate in the liver and its utilization in peripheral tissues. Biochimica et Biophysica Acta, 1532(1-2), 79-87.
13. Korsten, M. A., Matsuzaki, S., Feinman, L., & Lieber, C. S. (1975). High blood acetaldehyde levels after ethanol administration: Difference between alcoholic and nonalcoholic subjects. New England Journal of Medicine, 292(8), 386-389.
14. Lieber, C. S. (2005). Metabolism of alcohol. Clinics in Liver Disease, 9(1), 1-35.
15. Zakhari, S. (2006). Overview: How is alcohol metabolized by the body? Alcohol Research & Health, 29(4), 245-254.
16. Parlesak, A., Schafer, C., Schutz, T., Bode, J. C., & Bode, C. (2000). Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. Journal of Hepatology, 32(5), 742-747.
17. Jones, A. W., & Sternebring, B. (1992). Kinetics of ethanol and methanol in alcoholics during detoxification. Alcohol and Alcoholism, 27(6), 641-647.

18. Widmark, E. M. P. (1932). Die theoretischen Grundlagen und die praktische Verwendbarkeit der gerichtlich-medizinischen Alkoholbestimmung. Urban & Schwarzenberg.
19. Norberg, A., Jones, A. W., Hahn, R. G., & Gabrielsson, J. L. (2003). Role of variability in explaining ethanol pharmacokinetics. Clinical Pharmacokinetics, 42(1), 1-31.
20. Hurley, T. D., & Edenberg, H. J. (2012). Genes encoding enzymes involved in ethanol metabolism. Alcohol Research: Current Reviews, 34(3), 339-344.
21. Bosron, W. F., Ehrig, T., & Li, T. K. (1993). Genetic factors in alcohol metabolism and alcoholism. Seminars in Liver Disease, 13(2), 126-135.
22. Duester, G., Farrés, J., Felder, M. R., Holmes, R. S., Höög, J. O., Parés, X., ... & Yin, S. J. (1999). Recommended nomenclature for the vertebrate alcohol dehydrogenase gene family. Biochemical Pharmacology, 58(3), 389-395.
23. Thomasson, H. R., Edenberg, H. J., Crabb, D. W., Mai, X. L., Jerome, R. E., Li, T. K., ... & Yin, S. J. (1991). Alcohol and aldehyde dehydrogenase genotypes and alcoholism in Chinese men. American Journal of Human Genetics, 48(4), 677-681.
24. Chen, C. C., Lu, R. B., Chen, Y. C., Wang, M. F., Chang, Y. C., Li, T. K., & Yin, S. J. (1999). Interaction between the functional polymorphisms of the alcohol-metabolism genes in protection against alcoholism. American Journal of Human Genetics, 65(3), 795-807.
25. Peng, G. S., & Yin, S. J. (2009). Effect of the allelic variants of aldehyde dehydrogenase ALDH22 and alcohol dehydrogenase ADH1B2 on blood acetaldehyde concentrations. Human Genomics, 3(2), 121-127.
26. Yokoyama, A., & Omori, T. (2003). Genetic polymorphisms of alcohol and aldehyde dehydrogenases and risk for esophageal and head and neck cancers. Japanese Journal of Clinical Oncology, 33(3), 111-121.
27. Crabb, D. W., Matsumoto, M., Chang, D., & You, M. (2004). Overview of the role of alcohol dehydrogenase and aldehyde dehydrogenase and their variants in the genesis of alcohol-related pathology. Proceedings of the Nutrition Society, 63(1), 49-63.
28. Veech, R. L., Guynn, R., & Veloso, D. (1972). The time-course of the effects of ethanol on the redox and phosphorylation states of rat liver. Biochemical Journal, 127(2), 387-397.

29. Lieber, C. S., Spritz, N., & DeCarli, L. M. (1966). Role of dietary, adipose, and endogenously synthesized fatty acids in the pathogenesis of the alcoholic fatty liver. Journal of Clinical Investigation, 45(1), 51-62.
30. Krebs, H. A., Freedland, R. A., Hems, R., & Stubbs, M. (1969). Inhibition of hepatic gluconeogenesis by ethanol. Biochemical Journal, 112(1), 117-124.
31. Lieber, C. S., & DeCarli, L. M. (1970). Hepatic microsomal ethanol-oxidizing system: In vitro characteristics and adaptive properties in vivo. Journal of Biological Chemistry, 245(10), 2505-2512.
32. Lu, Y., & Cederbaum, A. I. (2008). CYP2E1 and oxidative liver injury by alcohol. Free Radical Biology and Medicine, 44(5), 723-738.
33. Takahashi, T., Lasker, J. M., Rosman, A. S., & Lieber, C. S. (1993). Induction of cytochrome P-4502E1 in the human liver by ethanol is caused by a corresponding increase in encoding messenger RNA. Hepatology, 17(2), 236-245.
34. Mishin, V. M., Gray, J. P., Heck, D. E., Laskin, D. L., & Laskin, J. D. (2010). Application of the Amplex red/horseradish peroxidase assay to measure hydrogen peroxide generation by recombinant microsomal enzymes. Free Radical Biology and Medicine, 48(11), 1485-1491.
35. Albano, E., French, S. W., & Ingelman-Sundberg, M. (1999). Hydroxyethyl radicals in ethanol hepatotoxicity. Frontiers in Bioscience, 4, D533-D540.
36. Caro, A. A., & Cederbaum, A. I. (2004). Oxidative stress, toxicology, and pharmacology of CYP2E1. Annual Review of Pharmacology and Toxicology, 44, 27-42.
37. Lieber, C. S. (1997). Cytochrome P-4502E1: Its physiological and pathological role. Physiological Reviews, 77(2), 517-544.
38. Zimmerman, H. J., & Maddrey, W. C. (1995). Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: Analysis of instances of therapeutic misadventure. Hepatology, 22(3), 767-773.
39. Handler, J. A., & Thurman, R. G. (1990). Catalase-dependent ethanol oxidation in perfused rat liver: Requirement for fatty-acid-stimulated H2O2 production by peroxisomes. European Journal of Biochemistry, 190(1), 133-138.
40. Keilin, D., & Hartree, E. F. (1945). Properties of catalase: Catalysis of coupled oxidation of alcohols. Biochemical Journal, 39(4), 293-301.
41. Aragon, C. M., Rogan, F., & Amit, Z. (1992). Ethanol metabolism in rat brain homogenates by a catalase-H2O2 system. Biochemical Pharmacology, 44(1), 93-98.

42. Cohen, G., Sinet, P. M., & Heikkila, R. (1980). Ethanol oxidation by rat brain in vivo. Alcoholism: Clinical and Experimental Research, 4(4), 366-370.
43. Aragon, C. M., & Amit, Z. (1993). The effect of 3-amino-1,2,4-triazole on voluntary ethanol consumption: Evidence for brain catalase involvement in the mechanism of action. Neuropharmacology, 32(11), 1289-1295.
44. Gemma, S., Vichi, S., & Testai, E. (2007). Metabolic and genetic factors contributing to alcohol induced effects and fetal alcohol syndrome. Neuroscience & Biobehavioral Reviews, 31(2), 221-229.
45. Lindahl, R. (1992). Aldehyde dehydrogenases and their role in carcinogenesis. Critical Reviews in Biochemistry and Molecular Biology, 27(4-5), 283-335.
46. Niemela, O. (2001). Distribution of ethanol-induced protein adducts in vivo: Relationship to tissue injury. Free Radical Biology and Medicine, 31(12), 1533-1538.
47. Salaspuro, M. (2003). Alcohol consumption and cancer of the gastrointestinal tract. Best Practice & Research Clinical Gastroenterology, 17(4), 679-694.
48. Homann, N., Tillonen, J., Meurman, J. H., Rintamäki, H., Lindqvist, C., Rautio, M., ... & Salaspuro, M. (2000). Increased salivary acetaldehyde levels in heavy drinkers and smokers: A microbiological approach to oral cavity cancer. Carcinogenesis, 21(4), 663-668.
49. Lachenmeier, D. W., & Salaspuro, M. (2017). ALDH2-deficiency as genetic epidemiologic and biochemical model for the carcinogenicity of acetaldehyde. Regulatory Toxicology and Pharmacology, 86, 128-136.
50. Marchitti, S. A., Brocker, C., Stagos, D., & Vasiliou, V. (2008). Non-P450 aldehyde oxidizing enzymes: The aldehyde dehydrogenase superfamily. Expert Opinion on Drug Metabolism & Toxicology, 4(6), 697-720.
51. Yoshida, A., Huang, I. Y., & Ikawa, M. (1984). Molecular abnormality of an inactive aldehyde dehydrogenase variant commonly found in Orientals. Proceedings of the National Academy of Sciences, 81(1), 258-261.
52. Stagos, D., Chen, Y., Cantore, M., Jester, J. V., & Vasiliou, V. (2010). Corneal aldehyde dehydrogenases: Multiple functions and novel nuclear localization. Brain Research Bulletin, 81(2-3), 211-218.
53. Brooks, P. J., Enoch, M. A., Goldman, D., Li, T. K., & Yokoyama, A. (2009). The alcohol flushing response: An unrecognized risk factor for esophageal cancer from alcohol consumption. PLoS Medicine, 6(3), e1000050.

54. Chen, Y. C., Lu, R. B., Peng, G. S., Wang, M. F., Wang, H. K., Ko, H. C., ... & Yin, S. J. (1999). Alcohol metabolism and cardiovascular response in an alcoholic patient homozygous for the ALDH2*2 variant gene allele. Alcoholism: Clinical and Experimental Research, 23(12), 1853-1860.

55. Higuchi, S., Matsushita, S., Murayama, M., Takagi, S., & Hayashida, M. (1995). Alcohol and aldehyde dehydrogenase polymorphisms and the risk for alcoholism. American Journal of Psychiatry, 152(8), 1219-1221.

56. Yokoyama, A., Muramatsu, T., Ohmori, T., Yokoyama, T., Okuyama, K., Takahashi, H., ... & Ishii, H. (1998). Alcohol-related cancers and aldehyde dehydrogenase-2 in Japanese alcoholics. Carcinogenesis, 19(8), 1383-1387.

57. Matsuo, K., Hamajima, N., Shinoda, M., Hatooka, S., Inoue, M., Takezaki, T., ... & Tajima, K. (2001). Gene-environment interaction between an aldehyde dehydrogenase-2 (ALDH2) polymorphism and alcohol consumption for the risk of esophageal cancer. Carcinogenesis, 22(6), 913-916.

58. Zhang, F. F., Hou, L., Terry, M. B., Lissowska, J., Morabia, A., Chen, J., ... & Santella, R. M. (2007). Genetic polymorphisms in alcohol metabolism, alcohol intake and the risk of stomach cancer in Warsaw, Poland. International Journal of Cancer, 121(9), 2060-2064.

59. Koppaka, V., Thompson, D. C., Chen, Y., Ellermann, M., Nicolaou, K. C., Juvonen, R. O., ... & Vasiliou, V. (2012). Aldehyde dehydrogenase inhibitors: A comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application. Pharmacological Reviews, 64(3), 520-539.

60. Lundquist, F., Tygstrup, N., Winkler, K., Mellemgaard, K., & Munck-Petersen, S. (1962). Ethanol metabolism and production of free acetate in the human liver. Journal of Clinical Investigation, 41(5), 955-961.

61. Skutches, C. L., Holroyde, C. P., Myers, R. N., Paul, P., & Reichard, G. A. (1979). Plasma acetate turnover and oxidation. Journal of Clinical Investigation, 64(3), 708-713.

62. Fujino, T., Kondo, J., Ishikawa, M., Morikawa, K., & Yamamoto, T. T. (2001). Acetyl-CoA synthetase 2, a mitochondrial matrix enzyme involved in the oxidation of acetate. Journal of Biological Chemistry, 276(14), 11420-11426.

63. Luong, A., Hannah, V. C., Brown, M. S., & Goldstein, J. L. (2000). Molecular characterization of human acetyl-CoA synthetase, an enzyme regulated by sterol

regulatory element-binding proteins. Journal of Biological Chemistry, 275(34), 26458-26466.

64. Siler, S. Q., Neese, R. A., & Hellerstein, M. K. (1999). De novo lipogenesis, lipid kinetics, and whole-body lipid balances in humans after acute alcohol consumption. American Journal of Clinical Nutrition, 70(5), 928-936.
65. Lands, W. E., & Zakhari, S. (1991). The case of the missing calories. American Journal of Clinical Nutrition, 54(1), 47-48.
66. Suter, P. M., Schutz, Y., & Jequier, E. (1992). The effect of ethanol on fat storage in healthy subjects. New England Journal of Medicine, 326(15), 983-987.
67. You, M., Fischer, M., Deeg, M. A., & Crabb, D. W. (2002). Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP). Journal of Biological Chemistry, 277(32), 29342-29347.
68. Vander Jagt, D. L., Daub, E., Krohn, J. A., & Han, L. P. B. (1975). Effects of pH and thiols on the kinetics of yeast aldehyde dehydrogenase. Biochemistry, 14(14), 3159-3163.
69. Esterbauer, H., Schaur, R. J., & Zollner, H. (1991). Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radical Biology and Medicine, 11(1), 81-128.
70. Lipscomb, J. C., Garrett, C. M., & Snawder, J. E. (1997). Cytochrome P450-dependent metabolism of trichloroethylene: Interindividual differences in humans. Toxicology and Applied Pharmacology, 142(2), 311-318.
71. Worrall, S., De Jersey, J., Shanley, B. C., & Wilce, P. A. (1989). Antibodies against acetaldehyde-modified epitopes: An elevated IgA response in alcoholics. European Journal of Clinical Investigation, 19(1), 90-94.
72. Mottaran, E., Stewart, S. F., Rolla, R., Vay, D., Cipriani, V., Moretti, M., ... & Albano, E. (2002). Lipid peroxidation contributes to immune reactions associated with alcoholic liver disease. Free Radical Biology and Medicine, 32(1), 38-45.
73. Israel, Y., Hurwitz, E., Niemela, O., & Arnon, R. (1986). Monoclonal and polyclonal antibodies against acetaldehyde-containing epitopes in acetaldehyde-protein adducts. Proceedings of the National Academy of Sciences, 83(20), 7923-7927.
74. Niemela, O., Parkkila, S., Yla-Herttuala, S., Villanueva, J., Ruebner, B., & Halsted, C. H. (1995). Sequential acetaldehyde production, lipid peroxidation, and fibrogenesis in micropig model of alcohol-induced liver disease. Hepatology, 22(4), 1208-1214.

75. Thiele, G. M., Tuma, D. J., Willis, M. S., Miller, J. A., McDonald, T. L., Sorrell, M. F., & Klassen, L. W. (1998). Soluble proteins modified with acetaldehyde and malondialdehyde are immunogenic in the absence of adjuvant. Alcoholism: Clinical and Experimental Research, 22(8), 1731-1739.

76. Matsuda, Y., Takada, A., & Takase, S. (1993). Effects of acetaldehyde on hepatocellular tight junction. Alcoholism: Clinical and Experimental Research, 17(2), 269-274.

77. Baraona, E., & Lieber, C. S. (1979). Effects of ethanol on lipid metabolism. Journal of Lipid Research, 20(3), 289-315.

78. Denk, H., Stumptner, C., & Zatloukal, K. (2000). Mallory bodies revisited. Journal of Hepatology, 32(4), 689-702.

79. Venkatraman, A., Landar, A., Davis, A. J., Chamlee, L., Sanderson, T., Kim, H., ... & Darley-Usmar, V. M. (2004). Modification of the mitochondrial proteome in response to the stress of ethanol-dependent hepatotoxicity. Journal of Biological Chemistry, 279(22), 22092-22101.

80. Bailey, S. M., & Cunningham, C. C. (2002). Contribution of mitochondria to oxidative stress associated with alcoholic liver disease. Free Radical Biology and Medicine, 32(1), 11-16.

81. Hoek, J. B., Cahill, A., & Pastorino, J. G. (2002). Alcohol and mitochondria: A dysfunctional relationship. Gastroenterology, 122(7), 2049-2063.

82. Wang, M., McIntee, E. J., Cheng, G., Shi, Y., Villalta, P. W., & Hecht, S. S. (2000). Identification of DNA adducts of acetaldehyde. Chemical Research in Toxicology, 13(11), 1149-1157.

83. Fang, J. L., & Vaca, C. E. (1997). Detection of DNA adducts of acetaldehyde in peripheral white blood cells of alcohol abusers. Carcinogenesis, 18(4), 627-632.

84. Matsuda, T., Terashima, I., Matsumoto, Y., Yabushita, H., Matsui, S., & Shibutani, S. (1999). Effective utilization of N2-ethyl-2'-deoxyguanosine triphosphate during DNA synthesis catalyzed by mammalian replicative DNA polymerases. Biochemistry, 38(3), 929-935.

85. Mechilli, M., Schinoppi, A., Kobos, K., Natarajan, A. T., & Palitti, F. (2008). DNA repair deficiency and acetaldehydeinduced chromosomal alterations in CHO cells. Mutagenesis, 23(1), 51-56.

86. Garaycoechea, J. I., Crossan, G. P., Langevin, F., Daly, M., Arends, M. J., & Patel, K. J. (2012). Genotoxic consequences of endogenous aldehydes on mouse haematopoietic stem cell function. Nature, 489(7417), 571-575.

87. Nagayoshi, H., Matsumoto, A., Nishi, R., Kawamoto, T., Ichiba, M., & Matsushita, T. (2009). Increased formation of gastric N(2)-ethylidene-2'-deoxyguanosine DNA adducts in aldehyde dehydrogenase-2 knockout mice treated with ethanol. Mutation Research, 673(1), 74-77.

88. Dellarco, V. L. (1988). A mutagenicity assessment of acetaldehyde. Mutation Research, 195(1), 1-20.

89. Theruvathu, J. A., Jaruga, P., Nath, R. G., Dizdaroglu, M., & Brooks, P. J. (2005). Polyamines stimulate the formation of mutagenic 1,N2-propanodeoxyguanosine adducts from acetaldehyde. Nucleic Acids Research, 33(11), 3513-3520.

90. Ishikawa, H., Yamamoto, H., Tian, Y., Kawano, M., Yamauchi, T., Yokoyama, A., ... & Muto, M. (2010). Effects of ALDH2 gene polymorphisms and alcohol-drinking behavior on micronuclei frequency in non-smokers. Mutation Research, 701(2), 145-150.

91. **[91]** Nordmann, R., Ribière, C., & Rouach, H. (1992). Implication of free radical mechanisms in ethanolinduced cellular injury. Free Radical Biology and Medicine, 12(3), 219-240.

92. Mira, L., Maia, L., Barreira, L., & Manso, C. F. (1995). Evidence for free radical generation due to NADH oxidation by aldehyde oxidase during ethanol metabolism. Archives of Biochemistry and Biophysics, 318(1), 53-58.

93. Kono, H., Rusyn, I., Yin, M., Gäbele, E., Yamashina, S., Dikalova, A., ... & Thurman, R. G. (2000). NADPH oxidase-derived free radicals are key oxidants in alcohol-induced liver disease. Journal of Clinical Investigation, 106(7), 867-872.

94. Petersen, D. R. (2005). Alcohol, iron-associated oxidative stress, and cancer. Alcohol, 35(3), 243-249.

95. Comporti, M. (1998). Lipid peroxidation and biogenic aldehydes: From the identification of 4-hydroxynonenal to further achievements in biopathology. Free Radical Research, 28(6), 623-635.

96. Poli, G., Schaur, R. J., Siems, W. G., & Leonarduzzi, G. (2008). 4-Hydroxynonenal: A membrane lipid oxidation product of medicinal interest. Medicinal Research Reviews, 28(4), 569-631.

97. Tuma, D. J. (2002). Role of malondialdehyde-acetaldehyde adducts in liver injury. Free Radical Biology and Medicine, 32(4), 303-308.

98. Videla, L. A., & Valenzuela, A. (1982). Alcohol ingestion, liver glutathione and lipoperoxidation: Metabolic interrelations and pathological implications. Life Sciences, 31(22), 2395-2407.

99. Wu, D., & Cederbaum, A. I. (2003). Alcohol, oxidative stress, and free radical damage. Alcohol Research & Health, 27(4), 277-284.

100. Fernández-Checa, J. C., Kaplowitz, N., García-Ruiz, C., Colell, A., Miranda, M., Marí, M., ... & Morales, A. (1997). GSH transport in mitochondria: Defense against TNF-induced oxidative stress and alcohol-induced defect. American Journal of Physiology, 273(1), G7-G17.

101. Swift, R., & Davidson, D. (1998). Alcohol hangover: Mechanisms and mediators. Alcohol Health and Research World, 22(1), 54-60.

102. Prat, G., Adan, A., & Sánchez-Turet, M. (2009). Alcohol hangover: A critical review of explanatory factors. Human Psychopharmacology, 24(4), 259-267.

103. Wiese, J. G., Shlipak, M. G., & Browner, W. S. (2000). The alcohol hangover. Annals of Internal Medicine, 132(11), 897-902.

104. Yokoyama, A., Yokoyama, T., Matsui, T., Mizukami, T., Kimura, M., Matsushita, S., ... & Nakao, H. (2010). Alcohol-related cancers and aldehyde dehydrogenase-2 in Japanese alcoholics. Carcinogenesis, 31(5), 856-865.

105. Jones, A. W. (1987). Elimination half-life of acetaldehyde in human subjects during prolonged ethanol oxidation. Alcoholism: Clinical and Experimental Research, 11(6), 494-498.

106. Verster, J. C., van Duin, D., Volkerts, E. R., Schreuder, A. H., & Verbaten, M. N. (2003). Alcohol hangover effects on driving performance in professional truck drivers. Alcoholism: Clinical and Experimental Research, 27(5), 803-809.

107. Penning, R., McKinney, A., & Verster, J. C. (2012). Alcohol hangover symptoms and their contribution to the overall hangover severity. Alcohol and Alcoholism, 47(3), 248-252.

108. Ylikahri, R. H., Huttunen, M. O., Eriksson, C. J., & Nikkilä, E. A. (1974). Metabolic studies on the pathogenesis of hangover. European Journal of Clinical Investigation, 4(2), 93-100.

109. Rohsenow, D. J., Howland, J., Minsky, S. J., Greece, J., Almeida, A., & Roehrs, T. A. (2007). The acute hangover scale: A new measure of immediate hangover symptoms. Addictive Behaviors, 32(6), 1314-1320.
110. Sippel, H. W. (1974). The acetaldehyde content in rat brain during ethanol metabolism. Journal of Neurochemistry, 23(3), 451-452.
111. Myers, R. D., & Melchior, C. L. (1977). Alcohol drinking: Abnormal intake caused by tetrahydropapaveroline in brain. Science, 196(4290), 554-556.
112. Rommelspacher, H., Strauss, S., & Lindemann, J. (1980). Excretion of tetrahydroharmane and harmane into the urine of man and rat after a load with ethanol. FEBS Letters, 109(2), 209-212.
113. Cohen, G., & Collins, M. (1970). Alkaloids from catecholamines in adrenal tissue: Possible role in alcoholism. Science, 167(3926), 1749-1751.
114. Deng, X. S., & Deitrich, R. A. (2007). Ethanol metabolism and effects: Nitric oxide and its interaction. Current Clinical Pharmacology, 2(2), 145-153.
115. Sjöquist, B., Perdahl, E., & Winblad, B. (1983). The effect of alcoholism on salsolinol and biogenic amines in human brain. Drug and Alcohol Dependence, 12(1), 15-23.
116. Quertemont, E., Tambour, S., & Tirelli, E. (2005). The role of acetaldehyde in the neurobehavioral effects of ethanol: A comprehensive review of animal studies. Progress in Neurobiology, 75(4), 247-274.
117. Smith, B. R., Amit, Z., & Splawinsky, J. (1984). Conditioned place preference induced by intraventricular infusions of acetaldehyde. Alcohol, 1(3), 193-195.
118. Zimatkin, S. M., Pronko, S. P., Vasiliou, V., Gonzalez, F. J., & Deitrich, R. A. (2006). Enzymatic mechanisms of ethanol oxidation in the brain. Alcoholism: Clinical and Experimental Research, 30(9), 1500-1505.
119. Orrego, H., Carmichael, F. J., Saldivia, V., Giles, H. G., Sandrin, S., & Israel, Y. (1988). Long-term ethanol intake in rats increases blood acetate levels. Life Sciences, 42(23), 2377-2382.
120. Tsukamoto, H., Mkrtchyan, H., & Dynnyk, A. (2008). Intragastric ethanol infusion model in rodents. Methods in Molecular Biology, 447, 33-48.
121. Crouse, J. R., Gerson, C. D., DeCarli, L. M., & Lieber, C. S. (1968). Role of acetate in the reduction of plasma free fatty acids produced by ethanol in man. Journal of Lipid Research, 9(4), 509-512.

122. Yki-Järvinen, H., Koivisto, V. A., Ylikahri, R., & Taskinen, M. R. (1988). Acute effects of ethanol and acetate on glucose kinetics in normal subjects. American Journal of Physiology, 254(2), E175-E180.

123. Nuutinen, H., Lindros, K. O., & Salaspuro, M. (1983). Determinants of blood acetate during ethanol oxidation in chronic alcoholics. Alcoholism: Clinical and Experimental Research, 7(2), 163-168.

124. Pouteau, E., Piloquet, H., Maugeais, P., Champ, M., Dumon, H., Nguyen, P., & Krempf, M. (1998). Kinetic aspects of acetate metabolism in healthy humans using [1-13C] acetate. American Journal of Physiology, 275(1), E58-E64.

125. Tremblay, A., Wouters, E., Wenker, M., St-Pierre, S., Bouchard, C., & Després, J. P. (1995). Alcohol and a high-fat diet: A combination favoring overfeeding. American Journal of Clinical Nutrition, 62(3), 639-644.

126. Suter, P. M. (2005). Is alcohol consumption a risk factor for weight gain and obesity? Critical Reviews in Clinical Laboratory Sciences, 42(3), 197-227.

127. Yeomans, M. R. (2010). Alcohol, appetite and energy balance: Is alcohol intake a risk factor for obesity? Physiology & Behavior, 100(1), 82-89.

128. Frost, G., Sleeth, M. L., Sahuri-Arisoylu, M., Lizarbe, B., Cerdan, S., Brody, L., ... & Bell, J. D. (2014). The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nature Communications, 5(1), 3611.

129. Wellen, K. E., Hatzivassiliou, G., Sachdeva, U. M., Bui, T. V., Cross, J. R., & Thompson, C. B. (2009). ATP-citrate lyase links cellular metabolism to histone acetylation. Science, 324(5930), 1076-1080.

130. Cai, L., Sutter, B. M., Li, B., & Tu, B. P. (2011). Acetyl-CoA induces cell growth and proliferation by promoting the acetylation of histones at growth genes. Molecular Cell, 42(4), 426-437.

131. Takahashi, H., McCaffery, J. M., Irizarry, R. A., & Boeke, J. D. (2006). Nucleocytosolic acetyl-coenzyme a synthetase is required for histone acetylation and global transcription. Molecular Cell, 23(2), 207-217.

132. Shukla, S. D., Velazquez, J., French, S. W., Lu, S. C., Ticku, M. K., & Zakhari, S. (2008). Emerging role of epigenetics in the actions of alcohol. Alcoholism: Clinical and Experimental Research, 32(9), 1525-1534.

133. Zakhari, S. (2013). Alcohol metabolism and epigenetics changes. Alcohol Research: Current Reviews, 35(1), 6-16.

134. Donohoe, D. R., & Bultman, S. J. (2012). Metaboloepigenetics: Interrelationships between energy metabolism and epigenetic control of gene expression. Journal of Cellular Physiology, 227(9), 3169-3177.

135. Mihaylova, M. M., & Shaw, R. J. (2011). The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nature Cell Biology, 13(9), 1016-1023.

136. Maslowski, K. M., Vieira, A. T., Ng, A., Kranich, J., Sierro, F., Yu, D., ... & Mackay, C. R. (2009). Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature, 461(7268), 1282-1286.

137. Trompette, A., Gollwitzer, E. S., Yadava, K., Sichelstiel, A. K., Sprenger, N., Ngom-Bru, C., & Marsland, B. J. (2014). Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nature Medicine, 20(2), 159-166.

138. Brown, A. J., Goldsworthy, S. M., Barnes, A. A., Eilert, M. M., Tcheang, L., Daniels, D., & Dowell, S. J. (2003). The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. Journal of Biological Chemistry, 278(13), 11312-11319.

139. Lanthier, N., & Leclercq, I. A. (2014). Adipose tissues as endocrine target organs. Best Practice & Research Clinical Gastroenterology, 28(4), 545-558.

140. Wang, H. J., Zakhari, S., & Jung, M. K. (2010). Alcohol, inflammation, and gut-liver-brain interactions in tissue damage and disease development. World Journal of Gastroenterology, 16(11), 1304-1313.

141. Ghosh, S., Molcan, E., DeCoffe, D., Dai, C., & Gibson, D. L. (2013). Diets rich in n-6 PUFA induce intestinal microbial dysbiosis in aged mice. British Journal of Nutrition, 110(3), 515-523.

142. Cresci, G. A., Glueck, B., McMullen, M. R., Xin, W., Allende, D., & Nagy, L. E. (2017). Prophylactic tributyrin treatment mitigates chronic-binge ethanol-induced intestinal barrier and liver injury. Journal of Gastroenterology and Hepatology, 32(9), 1587-1597.

143. Schnabl, B., & Brenner, D. A. (2014). Interactions between the intestinal microbiome and liver diseases. Gastroenterology, 146(6), 1513-1524.

144. Mutlu, E. A., Gillevet, P. M., Rangwala, H., Sikaroodi, M., Naqvi, A., Engen, P. A., ... & Keshavarzian, A. (2012). Colonic microbiome is altered in alcoholism. American Journal of Physiology-Gastrointestinal and Liver Physiology, 302(9), G966-G978.

145. Yan, A. W., Fouts, D. E., Brandl, J., Stärkel, P., Torralba, M., Schott, E., ... & Schnabl, B. (2011). Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology, 53(1), 96-105.

146. Salaspuro, V., Hietala, J., Kaihovaara, P., Pihlajarinne, L., Marvola, M., & Salaspuro, M. (2002). Removal of acetaldehyde from saliva by a slow-release buccal tablet of L-cysteine. International Journal of Cancer, 97(3), 361-364.

147. Parlesak, A., Schäfer, C., Schütz, T., Bode, J. C., & Bode, C. (2000). Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. Journal of Hepatology, 32(5), 742-747.

148. Elamin, E., Masclee, A., Dekker, J., & Jonkers, D. (2013). Ethanol metabolism and its effects on the intestinal epithelial barrier. Nutrition Reviews, 71(7), 483-499.

149. Peng, L., Li, Z. R., Green, R. S., Holzman, I. R., & Lin, J. (2009). Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. Journal of Nutrition, 139(9), 1619-1625.

150. Leclercq, S., Matamoros, S., Cani, P. D., Neyrinck, A. M., Jamar, F., Stärkel, P., ... & Delzenne, N. M. (2014). Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. Proceedings of the National Academy of Sciences, 111(42), E4485-E4493.

151. Bull-Otterson, L., Feng, W., Kirpich, I., Wang, Y., Qin, X., Liu, Y., ... & Barve, S. (2013). Metagenomic analyses of alcohol induced pathogenic alterations in the intestinal microbiome and the effect of Lactobacillus rhamnosus GG treatment. PloS One, 8(1), e53028.

152. Jiang, L., Gulanski, B. I., De Feyter, H. M., Weinzimer, S. A., Pittman, B., Guidone, E., ... & Mason, G. F. (2013). Increased brain uptake and oxidation of acetate in heavy drinkers. Journal of Clinical Investigation, 123(4), 1605-1614.

153. Waniewski, R. A., & Martin, D. L. (1998). Preferential utilization of acetate by astrocytes is attributable to transport. Journal of Neuroscience, 18(14), 5225-5233.

154. Volkow, N. D., Kim, S. W., Wang, G. J., Alexoff, D., Logan, J., Muench, L., ... & Fowler, J. S. (2013). Acute alcohol intoxication decreases glucose metabolism but increases acetate uptake in the human brain. NeuroImage, 64, 277-283.

155. Jiang, L., Herzog, R. I., Mason, G. F., de Graaf, R. A., Rothman, D. L., Sherwin, R. S., & Behar, K. L. (2009). Recalibrated hemodynamic and metabolic responses to

somatosensory stimulation. Journal of Cerebral Blood Flow & Metabolism, 29(6), 1276-1284.

156. Tucek, S. (1985). Regulation of acetylcholine synthesis in the brain. Journal of Neurochemistry, 44(1), 11-24.
157. Magistretti, P. J., & Allaman, I. (2015). A cellular perspective on brain energy metabolism and functional imaging. Neuron, 86(4), 883-901.
158. Verster, J. C. (2008). The alcohol hangover—A puzzling phenomenon. Alcohol and Alcoholism, 43(2), 124-126.
159. Stephens, R., Ling, J., Heffernan, T. M., Heather, N., & Jones, K. (2008). A review of the literature on the cognitive effects of alcohol hangover. Alcohol and Alcoholism, 43(2), 163-170.
160. Penning, R., van Nuland, M., Fliervoet, L. A., Olivier, B., & Verster, J. C. (2010). The pathology of alcohol hangover. Current Drug Abuse Reviews, 3(2), 68-75.
161. Gao, B., & Bataller, R. (2011). Alcoholic liver disease: Pathogenesis and new therapeutic targets. Gastroenterology, 141(5), 1572-1585.
162. Lucey, M. R., Mathurin, P., & Morgan, T. R. (2009). Alcoholic hepatitis. New England Journal of Medicine, 360(26), 2758-2769.
163. Purohit, V., Gao, B., & Song, B. J. (2009). Molecular mechanisms of alcoholic fatty liver. Alcoholism: Clinical and Experimental Research, 33(2), 191-205.
164. You, M., & Crabb, D. W. (2004). Molecular mechanisms of alcoholic fatty liver: Role of sterol regulatory element-binding proteins. Alcohol, 34(1), 39-43.
165. Sozio, M., & Crabb, D. W. (2008). Alcohol and lipid metabolism. American Journal of Physiology-Endocrinology and Metabolism, 295(1), E10-E16.
166. Day, C. P., & James, O. F. (1998). Steatohepatitis: A tale of two "hits"? Gastroenterology, 114(4), 842-845.
167. Tuma, D. J., & Casey, C. A. (2003). Dangerous byproducts of alcohol breakdown—Focus on adducts. Alcohol Research & Health, 27(4), 285-290.
168. Lin, R. C., Lumeng, L., Shahidi, S., Kelly, T., & Pound, D. C. (1990). Protein-acetaldehyde adducts in serum of alcoholic patients. Alcoholism: Clinical and Experimental Research, 14(3), 438-443.
169. Stewart, S. F., Vidali, M., Day, C. P., Albano, E., & Jones, D. E. (2004). Oxidative stress as a trigger for cellular immune responses in patients with alcoholic liver disease. Hepatology, 39(1), 197-203.

170. Mansouri, A., Gaou, I., De Kerguenec, C., Amsellem, S., Haouzi, D., Berson, A., ... & Pessayre, D. (1999). An alcoholic binge causes massive degradation of hepatic mitochondrial DNA in mice. Gastroenterology, 117(1), 181-190.

171. Mandrekar, P., & Szabo, G. (2009). Signalling pathways in alcohol-induced liver inflammation. Journal of Hepatology, 50(6), 1258-1266.

172. Svegliati-Baroni, G., Inagaki, Y., Rincon-Sanchez, A. R., Else, C., Saccomanno, S., Benedetti, A., ... & Brenner, D. A. (2005). Early response of α2(I) collagen to acetaldehyde in human hepatic stellate cells is TGF-β independent. Hepatology, 42(2), 343-352.

173. Tsukamoto, H., Machida, K., Dynnyk, A., & Mkrtchyan, H. (2009). "Second hit" models of alcoholic liver disease. Seminars in Liver Disease, 29(2), 178-187.

174. Piano, M. R. (2002). Alcoholic cardiomyopathy: Incidence, clinical characteristics, and pathophysiology. Chest, 121(5), 1638-1650.

175. Ronksley, P. E., Brien, S. E., Turner, B. J., Mukamal, K. J., & Ghali, W. A. (2011). Association of alcohol consumption with selected cardiovascular disease outcomes: A systematic review and meta-analysis. BMJ, 342, d671.

176. Ren, J., & Brown, R. A. (2000). Influence of chronic alcohol ingestion on acetaldehyde-induced depression of rat cardiac contractile function. Alcohol and Alcoholism, 35(6), 554-560.

177. Fauchier, L., Babuty, D., Poret, P., Casset-Senon, D., Autret, M. L., Cosnay, P., & Fauchier, J. P. (2000). Comparison of long-term outcome of alcoholic and idiopathic dilated cardiomyopathy. European Heart Journal, 21(4), 306-314.

178. Ren, J., Davidoff, A. J., & Brown, R. A. (1997). Acetaldehyde depresses shortening and intracellular Ca2+ transients in adult rat ventricular myocytes. Cellular and Molecular Biology, 43(6), 825-834.

179. Danziger, R. S., Sakai, M., Capogrossi, M. C., Spurgeon, H. A., Hansford, R. G., & Lakatta, E. G. (1991). Ethanol acutely and reversibly suppresses excitation-contraction coupling in cardiac myocytes. Circulation Research, 68(6), 1660-1668.

180. Jayasekara, H., English, D. R., Room, R., & MacInnis, R. J. (2014). Alcohol consumption over time and risk of death: A systematic review and meta-analysis. American Journal of Epidemiology, 179(9), 1049-1059.

181. Ware, L. B., & Matthay, M. A. (2005). Clinical practice. Acute pulmonary edema. New England Journal of Medicine, 353(26), 2788-2796.

182. Fernández-Solà, J., Nicolás, J. M., Oriola, J., Sacanella, E., Estruch, R., Rubin, E., & Urbano-Márquez, A. (2002). Angiotensin-converting enzyme gene polymorphism is associated with vulnerability to alcoholic cardiomyopathy. Annals of Internal Medicine, 137(5_Part_1), 321-326.

183. Ettinger, P. O., Wu, C. F., De La Cruz, C., Weisse, A. B., Ahmed, S. S., & Regan, T. J. (1978). Arrhythmias and the "Holiday Heart": Alcohol-associated cardiac rhythm disorders. American Heart Journal, 95(5), 555-562.

184. Greenspon, A. J., & Schaal, S. F. (1983). The "holiday heart": Electrophysiologic studies of alcohol effects in alcoholics. Annals of Internal Medicine, 98(2), 135-139.

185. Carmeliet, E. (2006). Alcohol and cardiac arrhythmias. Pacing and Clinical Electrophysiology, 29(12), 1334-1340.

186. Harper, C. (2009). The neuropathology of alcohol-related brain damage. Alcohol and Alcoholism, 44(2), 136-140.

187. Haorah, J., Ramirez, S. H., Floreani, N., Gorantla, S., Morsey, B., & Persidsky, Y. (2008). Mechanism of alcohol-induced oxidative stress and neuronal injury. Free Radical Biology and Medicine, 45(11), 1542-1550.

188. Haorah, J., Knipe, B., Leibhart, J., Ghorpade, A., & Persidsky, Y. (2005). Alcohol-induced oxidative stress in brain endothelial cells causes blood-brain barrier dysfunction. Journal of Leukocyte Biology, 78(6), 1223-1232.

189. Calabrese, V., Cornelius, C., Dinkova-Kostova, A. T., Iavicoli, I., Di Paola, R., Koverech, A., ... & Rizzarelli, E. (2012). Cellular stress responses, hormetic phytochemicals and vitagenes in aging and longevity. Biochimica et Biophysica Acta, 1822(5), 753-783.

190. Halliwell, B. (2006). Oxidative stress and neurodegeneration: Where are we now? Journal of Neurochemistry, 97(6), 1634-1658.

191. De la Monte, S. M., & Kril, J. J. (2014). Human alcohol-related neuropathology. Acta Neuropathologica, 127(1), 71-90.

192. Koike, H., Mori, K., Misu, K., Hattori, N., Ito, H., Hirayama, M., & Sobue, G. (2001). Painful alcoholic polyneuropathy with predominant small-fiber loss and normal thiamine status. Neurology, 56(12), 1727-1732.

193. Chopra, K., & Tiwari, V. (2012). Alcoholic neuropathy: Possible mechanisms and future treatment possibilities. British Journal of Clinical Pharmacology, 73(3), 348-362.

194. Dina, O. A., Levine, J. D., & Green, P. G. (2008). Muscle inflammation induces a protein kinase Cε-dependent chronic hyperalgesic priming via nicotinic acetylcholine receptor. Neuroscience, 152(2), 521-525.

195. Schwarzinger, M., Pollock, B. G., Hasan, O. S. M., Dufouil, C., Rehm, J., & QalyDays Study Group. (2018). Contribution of alcohol use disorders to the burden of dementia in France 2008–13: A nationwide retrospective cohort study. The Lancet Public Health, 3(3), e124-e132.

196. Venkataraman, A., Kalk, N., Sewell, G., Ritchie, C. W., & Lingford-Hughes, A. (2017). Alcohol and Alzheimer's disease—Does alcohol dependence contribute to beta-amyloid deposition, neuroinflammation and neurodegeneration in Alzheimer's disease? Alcohol and Alcoholism, 52(2), 158-163.

197. Panza, F., Frisardi, V., Seripa, D., Logroscino, G., Santamato, A., Imbimbo, B. P., ... & Solfrizzi, V. (2012). Alcohol consumption in mild cognitive impairment and dementia: Harmful or neuroprotective? International Journal of Geriatric Psychiatry, 27(12), 1218-1238.

198. Bode, C., & Bode, J. C. (2003). Effect of alcohol consumption on the gut. Best Practice & Research Clinical Gastroenterology, 17(4), 575-592.

199. Salaspuro, M. (2011). Acetaldehyde and gastric cancer. Journal of Digestive Diseases, 12(2), 51-59.